Emerging role of long noncoding RNA-encoded micropeptides in cancer

Increasing evidence has indicated that long noncoding RNAs (lncRNAs) play various important roles in the development of cancers. The widespread applications of ribosome profiling and ribosome nascent chain complex sequencing revealed that some short open reading frames of lncRNAs have micropeptide-c...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer cell international Ročník 20; číslo 1; s. 1 - 9
Hlavní autoři: Ye, Mujie, Zhang, Jingjing, Wei, Meng, Liu, Baihui, Dong, Kuiran
Médium: Journal Article
Jazyk:angličtina
Vydáno: London BioMed Central 16.10.2020
Springer Nature B.V
BMC
Témata:
Angiogenesis
Bioinformatics
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer
Cancer Research
Cell Biology
Cell growth
Coding potential
Drug development
Gene expression
Kinases
Liver cancer
lncRNA
Mass spectrometry
Medical prognosis
Micropeptide
N6-methyladenosine
Open reading frame
Open reading frames
Polypeptides
Proteins
Proteomics
Review
Ribonucleic acid
RNA
Roles
Scientific imaging
Signal transduction
Tumorigenesis
Vascular endothelial growth factor
lncRNA
Coding potential
Open reading frame
Micropeptide
Cancer
ISSN:1475-2867, 1475-2867
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Increasing evidence has indicated that long noncoding RNAs (lncRNAs) play various important roles in the development of cancers. The widespread applications of ribosome profiling and ribosome nascent chain complex sequencing revealed that some short open reading frames of lncRNAs have micropeptide-coding potential. The resulting micropeptides have been shown to participate in N6-methyladenosine modification, tumor angiogenesis, cancer metabolism, and signal transduction. This review summarizes current information regarding the reported roles of lncRNA-encoded micropeptides in cancer, and explores the potential clinical value of these micropeptides in the development of anti-cancer drugs and prognostic tumor biomarkers.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1475-2867
1475-2867
DOI:10.1186/s12935-020-01589-x